Does high-sensitivity C-reactive protein reflect systemic inflammation and cardiovascular risk?

At age 64, hs-CRP can be useful as a contextual cardiovascular risk marker, but its interpretation depends on clinical stability and the broader risk profile. The claim is well supported: systemic inflammation is linked mechanistically to impaired endothelial nitric-oxide (NO) signaling and to atherosclerotic disease progression.

Inflammatory marker and cardiovascular context

• hs-CRP measures circulating C-reactive protein, a liver-derived acute-phase protein principally induced by interleukin-6 (IL-6). It reflects overall systemic inflammatory activity rather than a specific vascular process or disease.
• Elevated hs-CRP is nonspecific: infection, injury, and metabolic conditions may increase it. CDC/AHA guidance recommends measurement in metabolically stable people on two occasions about two weeks apart, averaging results; a value >10 mg/L warrants repeat testing and consideration of an intercurrent inflammatory cause.
• ACC/AHA guidance recognizes hs-CRP ≥2.0 mg/L, when measured, as an ASCVD risk-enhancing factor—not a diagnosis or automatic indication for treatment.

Mechanistic pathway

• Inflammatory cytokines, especially TNF-α and IL-6, can increase NADPH-oxidase-derived superoxide, reduce eNOS expression and Ser1177 phosphorylation, and decrease NO availability.
• Superoxide reacts with NO to form peroxynitrite; oxidation of the eNOS cofactor BH₄ may uncouple eNOS, producing further superoxide. Reduced NO-mediated vasodilation is a central feature of endothelial dysfunction.
• Endothelial dysfunction promotes permeability, adhesion-molecule expression, and monocyte entry into the arterial wall, facilitating foam-cell accumulation and plaque development.

Clinical evidence

• In people with prior myocardial infarction and elevated hs-CRP, canakinumab reduced nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death (hazard ratio 0.85, 95% CI 0.74–0.98).
• Colchicine also reduced composite cardiovascular outcomes after recent myocardial infarction and in chronic coronary disease, supporting inflammation as a clinically consequential contributor to established atherosclerosis.

Bottom line

• hs-CRP is a valid but nonspecific indicator of systemic inflammation; inflammatory signaling can impair endothelial NO biology and actively promote atherosclerosis, making inflammatory status relevant to cardiovascular risk discussions.